The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 5
- 5 new
- Median first-year cost
- $2,931,750
- $12,985,966 in all
- Institutions
- 5
- 5 contact PIs
- Patents
- 1
- from 1 funded project
Awards by fiscal year
Fiscal years 2014 to 2026.
Most frequent institutions
- CHILDREN'S HOSP OF PHILADELPHIA1
- FRED HUTCHINSON CANCER RESEARCH CENTER1
- INDIANA UNIVERSITY INDIANAPOLIS1
- RESEARCH INST NATIONWIDE CHILDREN'S HOSP1
- UNIVERSITY OF COLORADO DENVER1
Most frequent study sections
- Special Emphasis Panel (ZRG1 OTC-Y (56))5
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2018 | Multispecific targeting incorporating cytokine receptor pathways in high risk pediatric acute leukemias to improve durability of adoptive cell therapy-induced remissions1U01CA232486-01 | Fry, Terry J.Tasian, Sarah Kathleen | UNIVERSITY OF COLORADO DENVER, CO | First-year cost $3,950,741 | Study section ZRG1 |
| FY2018 | Metabolic reprogramming of tumor microenvironment to maximize immunotherapy for pediatric cancers1U01CA232488-01 | Wang, Ruoning | RESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH | First-year cost $3,370,657 | Study section ZRG1 |
| FY2018 | Cassette exons in neoplastic pro-B-cells: implications for immunotherapy1U01CA232563-01 | Barash, YosephThomas-Tikhonenko, Andrei | CHILDREN'S HOSP OF PHILADELPHIA, PA | First-year cost $2,931,750 | Study section ZRG1 |
| FY2018 | Combinations of Synergistic Bispecific Human Antibodies: A Novel Strategy for the Treatment of Neuroblastoma1U01CA232490-01 | Olson, James M | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | First-year cost $1,543,917 | Study section ZRG1 |
| FY2018 | Dual targeting of tumoral microenvironment and tumoral cells by blocking the IL-33/ST2 pathway1U01CA232491-01 | Cheung, Nai-Kong VPaczesny, Sophie | INDIANA UNIVERSITY INDIANAPOLIS, IN | First-year cost $1,188,901 | Study section ZRG1 |
Patents from its funded projects
1 patent names 1 of the 5 funded projects.
- US 12,441,794 (opens the patent at USPTO, a PDF, in a new tab)ANTIBODIES FOR THE DIAGNOSIS AND TREATMENT OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAGranted October 14, 2025 to THE CHILDREN'S HOSPITAL OF PHILADELPHIAU01CA232563 · CHILDREN'S HOSP OF PHILADELPHIA, PA
Each number opens the patent at USPTO, beside the project NIH ties it to and that project's institution. NIH ties a patent to a project, not to a year of its funding, and says its list is incomplete. The grant date and the owners are USPTO's: the organizations the patent names as assignees on the day it was granted. Source: United States Patent and Trademark Office, www.uspto.gov, which does not endorse ScienceDex.
Data: Grants.gov's daily extract and NIH's notice pages, award files and patents file, in ScienceGraph release conductgrants-2026-11-21-0.3.10. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.